Automate Your Wheel Strategy on MRK
With Tiblio's Option Bot, you can configure your own wheel strategy including MRK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MRK
- Rev/Share 25.4145
- Book/Share 19.5994
- PB 4.2881
- Debt/Equity 0.7226
- CurrentRatio 1.4236
- ROIC 0.1828
- MktCap 209638944899.0
- FreeCF/Share 5.8814
- PFCF 14.2398
- PE 12.8056
- Debt/Assets 0.3012
- DivYield 0.0386
- ROE 0.3488
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | MRK | Berenberg | Buy | Hold | -- | $90 | Sept. 17, 2025 |
| Downgrade | MRK | Citigroup | Buy | Neutral | -- | $84 | May 14, 2025 |
| Initiation | MRK | Cantor Fitzgerald | -- | Neutral | -- | $85 | April 22, 2025 |
| Downgrade | MRK | Deutsche Bank | Buy | Hold | $128 | $105 | Feb. 18, 2025 |
| Downgrade | MRK | TD Cowen | Buy | Hold | $121 | $100 | Feb. 10, 2025 |
| Downgrade | MRK | Truist | Buy | Hold | -- | $110 | Jan. 8, 2025 |
| Downgrade | MRK | BMO Capital Markets | Outperform | Market Perform | $136 | $105 | Dec. 20, 2024 |
| Resumed | MRK | BofA Securities | -- | Buy | -- | $121 | Dec. 10, 2024 |
| Upgrade | MRK | HSBC Securities | Hold | Buy | -- | $130 | Dec. 4, 2024 |
| Initiation | MRK | Bernstein | -- | Market Perform | -- | $115 | Oct. 17, 2024 |
News
Rosen Law Firm Encourages Merck & Co. Inc. Investors to Inquire About Securities Class Action Investigation – MRK
Published: February 12, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Merck & Co. Inc. (NYSE: MRK) resulting from allegations that Merck may have issued materially misleading business information to the investing public. So What: If you purchased Merck securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The R.
Read More
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Merck & Co., Inc. Securities and Sets a Lead Plaintiff Deadline of April 14, 2025
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Merck & Co., Inc. (“Merck” or the “Company”) (NYSE: MRK) between February 3, 2022 to February 3, 2025, both dates inclusive. You are hereby notified that the class action lawsuit Michael Cronin v.
Read More
Jim Cramer Says These 2 Large Cap Dividend Stocks Are Hot February Buys
Published: February 11, 2025 by: 24/7 Wall Street
Sentiment: Positive
Media personality Jim Cramer often makes bold statements about companies and a lot of times, he proves himself correct.
Read More
Merck: 4 No-Brainer Reasons to Buy This Dip
Published: February 10, 2025 by: MarketBeat
Sentiment: Neutral
Big pharma has come under a lot of scrutiny from regulators and consumers as sentiment sours on the industry. As such, the market can be unforgiving when companies even slightly miss expectations or forecasts.
Read More
Better High-Yield Dividend Stock: Pfizer vs. Merck
Published: February 10, 2025 by: The Motley Fool
Sentiment: Positive
Investors looking for ways to pump up their passive income streams might want to turn their heads toward the pharmaceutical industry. At recent prices, you can buy shares of Merck (MRK -0.88%) that offer a yield above 3%, and shares of Pfizer (PFE -0.35%) offer a yield above 6%.
Read More
About Merck & Co., Inc. (MRK)
- IPO Date 1978-01-13
- Website https://www.merck.com
- Industry Drug Manufacturers - General
- CEO Robert M. Davis
- Employees 73000